Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Neural basis of smoking-induced relief of craving and negative affect: Contribution of nicotine.

Faulkner P, Ghahremani DG, Tyndale RF, Paterson NE, Cox C, Ginder N, Hellemann G, London ED.

Addict Biol. 2019 Sep;24(5):1087-1095. doi: 10.1111/adb.12679. Epub 2018 Oct 11.

PMID:
30307083
2.

N,N-Dimethyltryptamine-Induced Psychosis.

Paterson NE, Darby WC, Sandhu PS.

Clin Neuropharmacol. 2015 Jul-Aug;38(4):141-3. doi: 10.1097/WNF.0000000000000078.

PMID:
26166234
3.

Cognitive deficits in transgenic and knock-in HTT mice parallel those in Huntington's disease.

Farrar AM, Murphy CA, Paterson NE, Oakeshott S, He D, Alosio W, McConnell K, Menalled LB, Ramboz S, Park LC, Howland D, Brunner D.

J Huntingtons Dis. 2014;3(2):145-58. doi: 10.3233/JHD-130061.

PMID:
25062858
4.

Dopamine D3 receptors as a therapeutic target for methamphetamine dependence.

Paterson NE, Vocci F, Sevak RJ, Wagreich E, London ED.

Am J Drug Alcohol Abuse. 2014 Jan;40(1):1-9. doi: 10.3109/00952990.2013.858723. Review.

PMID:
24359505
5.

Assessment of substance abuse liability in rodents: self-administration, drug discrimination, and locomotor sensitization.

Paterson NE.

Curr Protoc Pharmacol. 2012 Sep;Chapter 5:Unit5.62. doi: 10.1002/0471141755.ph0562s58.

PMID:
22948849
6.

Difficulties in disclosing the diagnosis of dementia: a qualitative study in general practice.

Phillips J, Pond CD, Paterson NE, Howell C, Shell A, Stocks NP, Goode SM, Marley JE.

Br J Gen Pract. 2012 Aug;62(601):e546-53. doi: 10.3399/bjgp12X653598.

7.

Chemistry and behavioral studies identify chiral cyclopropanes as selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile.

Zhang H, Tückmantel W, Eaton JB, Yuen PW, Yu LF, Bajjuri KM, Fedolak A, Wang D, Ghavami A, Caldarone B, Paterson NE, Lowe DA, Brunner D, Lukas RJ, Kozikowski AP.

J Med Chem. 2012 Jan 26;55(2):717-24. doi: 10.1021/jm201157c. Epub 2012 Jan 10.

8.

Impulsive action and impulsive choice are mediated by distinct neuropharmacological substrates in rat.

Paterson NE, Wetzler C, Hackett A, Hanania T.

Int J Neuropsychopharmacol. 2012 Nov;15(10):1473-87. doi: 10.1017/S1461145711001635. Epub 2011 Nov 18.

PMID:
22094071
9.

Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380.

Caldarone BJ, Wang D, Paterson NE, Manzano M, Fedolak A, Cavino K, Kwan M, Hanania T, Chellappan SK, Kozikowski AP, Olivier B, Picciotto MR, Ghavami A.

Psychopharmacology (Berl). 2011 Sep;217(2):199-210. doi: 10.1007/s00213-011-2271-y. Epub 2011 Apr 13.

10.

Both GABA(B) receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats.

Vlachou S, Paterson NE, Guery S, Kaupmann K, Froestl W, Banerjee D, Finn MG, Markou A.

Eur J Pharmacol. 2011 Mar 25;655(1-3):52-8. doi: 10.1016/j.ejphar.2011.01.009. Epub 2011 Jan 22.

11.

Translational research in addiction: toward a framework for the development of novel therapeutics.

Paterson NE.

Biochem Pharmacol. 2011 Jun 15;81(12):1388-407. doi: 10.1016/j.bcp.2010.12.017. Epub 2011 Jan 7. Review.

PMID:
21216239
12.

Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone.

Paterson NE, Ricciardi J, Wetzler C, Hanania T.

Neurosci Res. 2011 Jan;69(1):41-50. doi: 10.1016/j.neures.2010.10.001. Epub 2010 Oct 8.

PMID:
20934466
13.

The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.

Caldarone BJ, Paterson NE, Zhou J, Brunner D, Kozikowski AP, Westphal KG, Korte-Bouws GA, Prins J, Korte SM, Olivier B, Ghavami A.

J Pharmacol Exp Ther. 2010 Dec;335(3):762-70. doi: 10.1124/jpet.110.174011. Epub 2010 Sep 23.

14.

The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.

Paterson NE, Min W, Hackett A, Lowe D, Hanania T, Caldarone B, Ghavami A.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1455-64. doi: 10.1016/j.pnpbp.2010.07.037. Epub 2010 Aug 11.

PMID:
20708056
15.

Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.

Paterson NE, Fedolak A, Olivier B, Hanania T, Ghavami A, Caldarone B.

Pharmacol Biochem Behav. 2010 Jun;95(4):449-56. doi: 10.1016/j.pbb.2010.03.006. Epub 2010 Mar 25.

16.

The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition.

Paterson NE, Balci F, Campbell U, Olivier BE, Hanania T.

J Psychopharmacol. 2011 Oct;25(10):1357-64. doi: 10.1177/0269881110364272. Epub 2010 Mar 19.

PMID:
20305042
17.

Comparison of the predictive validity of the mirror chamber and elevated plus maze tests in mice.

Paterson NE, Iwunze M, Davis SF, Malekiani SA, Hanania T.

J Neurosci Methods. 2010 Apr 30;188(1):62-70. doi: 10.1016/j.jneumeth.2010.02.005. Epub 2010 Feb 10.

PMID:
20149823
18.

The modified Geller-Seifter test in rats was insensitive to GABAB receptor positive modulation or blockade, or 5-HT1A receptor activation.

Paterson NE, Hanania T.

Behav Brain Res. 2010 Mar 17;208(1):258-64. doi: 10.1016/j.bbr.2009.12.006. Epub 2009 Dec 16.

PMID:
20006648
19.

Pharmacological characterization of harmaline-induced tremor activity in mice.

Paterson NE, Malekiani SA, Foreman MM, Olivier B, Hanania T.

Eur J Pharmacol. 2009 Aug 15;616(1-3):73-80. doi: 10.1016/j.ejphar.2009.05.031. Epub 2009 Jun 2.

PMID:
19497322
20.

The neuropharmacological substrates of nicotine reward: reinforcing versus reinforcement-enhancing effects of nicotine.

Paterson NE.

Behav Pharmacol. 2009 May;20(3):211-25. doi: 10.1097/FBP.0b013e32832c7083. Review.

PMID:
19421028
21.

Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights.

Paterson NE.

Eur J Pharmacol. 2009 Jan 28;603(1-3):1-11. doi: 10.1016/j.ejphar.2008.12.009. Epub 2008 Dec 16. Review.

PMID:
19101536
22.

Multiple motivational forces contribute to nicotine dependence.

Markou A, Paterson NE.

Nebr Symp Motiv. 2009;55:65-89. Review. No abstract available.

PMID:
19013939
23.

Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats.

Paterson NE, Balfour DJ, Markou A.

Nicotine Tob Res. 2008 Jun;10(6):995-1008. doi: 10.1080/14622200802097571.

PMID:
18584463
24.

Positive modulation of GABA(B) receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats.

Paterson NE, Vlachou S, Guery S, Kaupmann K, Froestl W, Markou A.

J Pharmacol Exp Ther. 2008 Jul;326(1):306-14. doi: 10.1124/jpet.108.139204. Epub 2008 Apr 29.

25.

The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat.

Paterson NE, Semenova S, Markou A.

Psychopharmacology (Berl). 2008 Jun;198(3):351-62. doi: 10.1007/s00213-008-1144-5. Epub 2008 Apr 29.

26.
27.

Animal models and treatments for addiction and depression co-morbidity.

Paterson NE, Markou A.

Neurotox Res. 2007 Jan;11(1):1-32. Review.

PMID:
17449445
28.

Extended access to nicotine self-administration leads to dependence: Circadian measures, withdrawal measures, and extinction behavior in rats.

O'Dell LE, Chen SA, Smith RT, Specio SE, Balster RL, Paterson NE, Markou A, Zorrilla EP, Koob GF.

J Pharmacol Exp Ther. 2007 Jan;320(1):180-93. Epub 2006 Oct 18.

PMID:
17050784
29.

Prolonged nicotine exposure does not alter GABA(B) receptor-mediated regulation of brain reward function.

Paterson NE, Bruijnzeel AW, Kenny PJ, Wright CD, Froestl W, Markou A.

Neuropharmacology. 2005 Dec;49(7):953-62. Epub 2005 Jul 7.

PMID:
16005474
30.

The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats.

Paterson NE, Markou A.

Psychopharmacology (Berl). 2005 Apr;179(1):255-61. Epub 2004 Dec 24.

PMID:
15619120
31.
33.

Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats.

Paterson NE, Markou A.

Psychopharmacology (Berl). 2004 Apr;173(1-2):64-72. Epub 2004 Jan 8.

PMID:
14712336
34.

Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats.

Kenny PJ, Paterson NE, Boutrel B, Semenova S, Harrison AA, Gasparini F, Koob GF, Skoubis PD, Markou A.

Ann N Y Acad Sci. 2003 Nov;1003:415-8. No abstract available.

PMID:
14684476
35.

Increased motivation for self-administered cocaine after escalated cocaine intake.

Paterson NE, Markou A.

Neuroreport. 2003 Dec 2;14(17):2229-32.

PMID:
14625453
36.

The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat.

Paterson NE, Froestl W, Markou A.

Psychopharmacology (Berl). 2004 Mar;172(2):179-86. Epub 2003 Nov 11.

PMID:
14610636
37.

The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice.

Paterson NE, Semenova S, Gasparini F, Markou A.

Psychopharmacology (Berl). 2003 May;167(3):257-64. Epub 2003 Apr 8.

PMID:
12682710
38.

Increased GABA neurotransmission via administration of gamma-vinyl GABA decreased nicotine self-administration in the rat.

Paterson NE, Markou A.

Synapse. 2002 Jun 15;44(4):252-3. No abstract available.

PMID:
11984860
40.

Effects of repeated withdrawal from continuous amphetamine administration on brain reward function in rats.

Paterson NE, Myers C, Markou A.

Psychopharmacology (Berl). 2000 Nov;152(4):440-6.

PMID:
11140337

Supplemental Content

Loading ...
Support Center